ACAD Signs License Deal With Saniona for Rights to Neurology Drug [Yahoo! Finance]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Yahoo! Finance
biopharmaceutical company, to develop and commercialize SAN711, a first-in-class, highly selective GABA A -a3 positive allosteric modulator. As its first indication, Acadia plans to study SAN711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the body. The company is gearing up to initiate a mid-stage study of the candidate for the essential tremor indication in 2026. This strategic move aligns with ACAD's longstanding commitment to delivering innovative therapies for patients with central nervous system disorders. Per the company, essential tremor has lacked innovative treatment options for decades, highlighting a significant unmet need. Leveraging Acadia's extensive expertise in developing and commercializing advanced therapies for neurological disorders, the company aims to address this gap through its work with SAN711. Year to date, shares of Acadia have plunged 48.2% compared with the industry's 7.8% declin
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025Business Wire
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 MillionBusiness Wire
ACAD
Earnings
- 11/6/24 - Beat
ACAD
Sec Filings
- 12/11/24 - Form 8-K
- 12/10/24 - Form 4
- 12/10/24 - Form 3
- ACAD's page on the SEC website